Gilead Sciences, Compugen Ink Exclusive License Agreement For Novel Pre-Clinical Immunotherapy Program In Total Deal Value Of Up To $848M
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has entered into an exclusive license agreement with Compugen for a pre-clinical immunotherapy program, potentially worth up to $848 million. Gilead will pay Compugen $60 million upfront, $30 million upon IND clearance of COM503, and up to $758 million in additional milestone payments. Compugen is also set to receive royalties on worldwide net sales.
December 19, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen receives a significant financial commitment from Gilead Sciences, including an upfront payment and potential future milestones, which could provide a substantial boost to its funding and development capabilities.
The agreement provides immediate financial benefits to Compugen and the potential for significant future earnings. This influx of capital is likely to be viewed positively by investors, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Gilead Sciences' new agreement with Compugen could enhance its pipeline with a novel immunotherapy program, representing a significant investment in future potential.
The deal could positively impact Gilead's stock in the short term as it reflects the company's commitment to expanding its immunotherapy portfolio, which is a high-interest area in biotech. The substantial financial commitment indicates a strong belief in the potential of the program.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80